RecensMedical Inc., a UNIST-based faculty startup company founded by Professor Gun-Ho Kim (Department of Mechanical Engineering), has recently been honored with the ‘$5 Million Export Tower’ award at the 59th Trade Day Ceremony, which was held at Convention and Exhibition (COEX) on December 5, 2022.
The $5 Million Export Tower award is an award, given to companies that contributed significantly to increasing in overseas exports of Korea based on their export performance. RecensMedical Inc. had the honor of being given the award for accomplishing export growth and expanding in markets abroad with their non-contact precision cooling treatment device, namely ‘TargetCool‘.
‘TargetCool‘ is a revolutionary FDA Class II/ MFDS Class III/ CE Class ll medical device that provides precise, controlled tissue cooling. It uses cryogenic refrigerant (CO₂) to control the target temperature to rapidly cool the affected area, minimizing injection-related pain and inflammation.
Established in 2016, RecensMedical Inc. is an innovative tech company based on ‘Rapid Precision Temperature Control Technology‘ (60 patent applications). In addition, the company has established itself as a leading company in the precision cooling medical field through R&D and commercialization for optimal cooling treatment.
The company has also established CoolHealth Inc. in the U.S., a country that accounted for 50% of the global skincare device market at the time of 2021. The company further achieved $5 million in export in 2022, a year after it began full-fledged business activities, including the establishment of a strategic partnership with Westlake Dermatology Inc., a leading provider of medical aesthetic solutions in the U.S.
“RecensMedical Inc. strives to provide the best clinical results for medical staff and safe medical experience by drastically reducing the time and patient pain with its unique cooling technology,” says Professor Gun-Ho Kim (CEO, RecensMedical Inc.). “We will do our best to provide excellent products that can add value to medical services in the global medical market next year.”
